WO1997018300A2 - Murine model for human carcinoma - Google Patents

Murine model for human carcinoma Download PDF

Info

Publication number
WO1997018300A2
WO1997018300A2 PCT/US1996/018243 US9618243W WO9718300A2 WO 1997018300 A2 WO1997018300 A2 WO 1997018300A2 US 9618243 W US9618243 W US 9618243W WO 9718300 A2 WO9718300 A2 WO 9718300A2
Authority
WO
WIPO (PCT)
Prior art keywords
human
mouse
carcinoma
tumor
immunodeficient mouse
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1996/018243
Other languages
English (en)
French (fr)
Other versions
WO1997018300A3 (en
Inventor
Elizabeth Repasky Subjeck
Harvey Bumpers
Heather Secrist
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corixa Corp
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Priority to AU11589/97A priority Critical patent/AU1158997A/en
Priority to JP9519058A priority patent/JP2000500653A/ja
Priority to AT96942749T priority patent/ATE261654T1/de
Priority to DE69631896T priority patent/DE69631896D1/de
Priority to EP96942749A priority patent/EP0866655B1/en
Priority to CA 2237300 priority patent/CA2237300C/en
Publication of WO1997018300A2 publication Critical patent/WO1997018300A2/en
Publication of WO1997018300A3 publication Critical patent/WO1997018300A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Definitions

  • the present invention provides murine models for breast, ovarian and prostate carcinomas.
  • an immunodeficient mouse containing human primary breast, ovarian or prostate carcinoma tissue is provided, wherein the carcinoma tissue is implanted within a gonadal fat pad of the immunodeficient mouse.
  • an immunodeficient mouse is provided in which prostate carcinoma tissue is implanted subcutaneously.
  • the present invention provides methods for generating a murine model for breast, ovarian or prostate cancer.
  • the method comprises implanting a specimen of a human breast, ovarian or prostate carcinoma within the gonadal fat pad (or alternatively, subcutaneously for prostate carcinoma) of an immunodeficient mouse.
  • the method further comprises removing a portion of the implanted carcinoma specimen and subsequently implanting the portion within a gonadal fat pad (or subcutaneously) of a second immunodeficient mouse.
  • binding assays may be performed using any of a variety of methods known to those of ordinary skill in the art, such as those described in Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988. Suitable methods include, but are not limited to, radioimmunoprecipitation, enzyme-linked immunosorbent assays and western blot assays.
  • Treatments can be administered via multiple routes including by subcutaneous, intravenous, intraperitoneal, or intradermal injection. Following a course of therapy, efficacy can be assessed by determination of relative survival, and tumor growth rates in cohorts of tumor-bearing mice who receive gene therapy vs. tumor-bearing mice that receive either no treatment or treatment with a placebo.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Environmental Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Animal Husbandry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PCT/US1996/018243 1995-11-13 1996-11-13 Murine model for human carcinoma Ceased WO1997018300A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU11589/97A AU1158997A (en) 1995-11-13 1996-11-13 Murine model for human carcinoma
JP9519058A JP2000500653A (ja) 1995-11-13 1996-11-13 ヒト癌のマウスモデル
AT96942749T ATE261654T1 (de) 1995-11-13 1996-11-13 Murines modell für menschliche karzinome
DE69631896T DE69631896D1 (de) 1995-11-13 1996-11-13 Murines modell für menschliche karzinome
EP96942749A EP0866655B1 (en) 1995-11-13 1996-11-13 Murine model for human carcinoma
CA 2237300 CA2237300C (en) 1995-11-13 1996-11-13 Murine model for human carcinoma

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/556,659 US5986170A (en) 1995-11-13 1995-11-13 Murine model for human carcinoma
US08/556,659 1995-11-13

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US08/556,659 Continuation-In-Part US5986170A (en) 1995-11-13 1995-11-13 Murine model for human carcinoma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/078,207 Continuation-In-Part US6284239B1 (en) 1995-11-13 1998-05-13 Murine model for human carcinoma

Publications (2)

Publication Number Publication Date
WO1997018300A2 true WO1997018300A2 (en) 1997-05-22
WO1997018300A3 WO1997018300A3 (en) 1997-07-24

Family

ID=24222286

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/018243 Ceased WO1997018300A2 (en) 1995-11-13 1996-11-13 Murine model for human carcinoma

Country Status (7)

Country Link
US (2) US5986170A (cg-RX-API-DMAC7.html)
EP (1) EP0866655B1 (cg-RX-API-DMAC7.html)
JP (1) JP2000500653A (cg-RX-API-DMAC7.html)
AT (1) ATE261654T1 (cg-RX-API-DMAC7.html)
AU (1) AU1158997A (cg-RX-API-DMAC7.html)
DE (1) DE69631896D1 (cg-RX-API-DMAC7.html)
WO (1) WO1997018300A2 (cg-RX-API-DMAC7.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999019479A1 (en) * 1997-09-26 1999-04-22 Corixa Corporation Murine model for human carcinoma
US6284239B1 (en) 1995-11-13 2001-09-04 Corixa Corporation Murine model for human carcinoma
EP2022800A2 (en) 2000-07-17 2009-02-11 Corixa Corporation Compositions for the therapy and diagnosis of ovarian cancer
US8598408B2 (en) 2010-08-25 2013-12-03 Ordermade Medical Research Inc. Method of producing an antibody using a cancer cell

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6730512B2 (en) * 1997-04-09 2004-05-04 Amdl, Inc. Combination immunogene therapy
US20040033230A1 (en) * 1997-12-24 2004-02-19 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6623923B1 (en) 1998-12-23 2003-09-23 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
US20050260177A1 (en) * 1998-06-05 2005-11-24 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
US6573368B2 (en) 1998-12-28 2003-06-03 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US6518237B1 (en) 1998-12-28 2003-02-11 Corixa Corporation Compositions for treatment and diagnosis of breast cancer and methods for their use
US6528054B1 (en) 1998-12-28 2003-03-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6958361B2 (en) * 1998-12-28 2005-10-25 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US6590076B1 (en) * 1999-04-02 2003-07-08 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US6969518B2 (en) * 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6387697B1 (en) 1998-12-28 2002-05-14 Corixa Corporation Compositions for treatment and diagnosis of breast cancer and methods for their use
US6844325B2 (en) 1998-12-28 2005-01-18 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US6586572B2 (en) 1998-12-28 2003-07-01 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US7598226B2 (en) * 1998-12-28 2009-10-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6680197B2 (en) 1998-12-28 2004-01-20 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
EP1248800A2 (en) * 1999-11-30 2002-10-16 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
US7315838B2 (en) 2000-04-13 2008-01-01 Superderivatives, Inc. Method and system for pricing options
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US20080194022A1 (en) * 2000-08-03 2008-08-14 Clarke Michael F Isolation and use of solid tumor stem cells
IL161353A0 (en) 2001-10-13 2004-09-27 Superderivatives Inc Method and system for pricing financial derivatives
WO2005005601A2 (en) * 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20050232927A1 (en) * 2004-02-03 2005-10-20 The Regents Of The University Of Michigan Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
US20070099209A1 (en) * 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2007053648A2 (en) 2005-10-31 2007-05-10 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
ES2547421T3 (es) 2005-10-31 2015-10-06 Oncomed Pharmaceuticals, Inc. Composiciones y métodos para diagnosticar y tratar el cáncer
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
US8148147B2 (en) * 2007-01-24 2012-04-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
KR101711672B1 (ko) 2008-09-26 2017-03-03 온코메드 파마슈티칼스, 인크. 프리즐드 결합 작용제 및 그의 용도
JP5688699B2 (ja) * 2009-02-27 2015-03-25 株式会社オーダーメードメディカルリサーチ がん細胞を用いた免疫方法
US8626630B2 (en) 2010-01-04 2014-01-07 Super Derivatives, Inc. Device, method and system of pricing financial instruments
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
CA2794674A1 (en) 2010-04-01 2011-10-06 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
US20140047570A1 (en) * 2011-04-19 2014-02-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Animal model of human cancer and methods of use
AU2013334790A1 (en) 2012-10-23 2015-04-30 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using Wnt pathway-binding agents
WO2014121196A1 (en) 2013-02-04 2014-08-07 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a wnt pathway inhibitor
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3853201T2 (de) * 1987-12-23 1995-09-14 Univ Leland Stanford Junior Schimäre immunkompromittierende Säugetiere und ihre Verwendung.
US5491284A (en) * 1988-10-05 1996-02-13 Anticancer Incorporated Nude mouse model for neoplastic disease
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
DE69120890T2 (de) * 1990-05-03 1997-02-20 Systemix Inc Menschliches lymph-gewebe in einem wirt mit angegriffenem immunsystem
JPH04252128A (ja) * 1990-08-03 1992-09-08 Systemix Inc 免疫化された宿主における変性された異種移植器官系
EP0552336A1 (en) * 1991-08-02 1993-07-28 Systemix, Inc. Primordial implants in immunodeficient hosts
US5986170A (en) * 1995-11-13 1999-11-16 Corixa Corporation Murine model for human carcinoma

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284239B1 (en) 1995-11-13 2001-09-04 Corixa Corporation Murine model for human carcinoma
WO1999019479A1 (en) * 1997-09-26 1999-04-22 Corixa Corporation Murine model for human carcinoma
EP2022800A2 (en) 2000-07-17 2009-02-11 Corixa Corporation Compositions for the therapy and diagnosis of ovarian cancer
US8598408B2 (en) 2010-08-25 2013-12-03 Ordermade Medical Research Inc. Method of producing an antibody using a cancer cell

Also Published As

Publication number Publication date
US6284239B1 (en) 2001-09-04
AU1158997A (en) 1997-06-05
US5986170A (en) 1999-11-16
WO1997018300A3 (en) 1997-07-24
EP0866655A2 (en) 1998-09-30
EP0866655B1 (en) 2004-03-17
DE69631896D1 (de) 2004-04-22
ATE261654T1 (de) 2004-04-15
JP2000500653A (ja) 2000-01-25

Similar Documents

Publication Publication Date Title
US5986170A (en) Murine model for human carcinoma
JP4267692B2 (ja) 前立腺癌の免疫療法のための樹状細胞の単離および／または保存
Mueller et al. Potential of the scid mouse as a host for human tumors
CN104906139B (zh) 异源造血干细胞移植的增强
Botzler et al. Differential Hsp70 plasma‐membrane expression on primary human tumors and metastases in mice with severe combined immunodeficiency
CA2278678A1 (en) Cancer immunotherapy with semi-allogeneic cells
US20020006413A1 (en) Genetically engineered tumor cell vaccines
WO1999019479A1 (en) Murine model for human carcinoma
Ishida et al. Effects of the deregulated expression of human interleukin-2 in transgenic mice
US20110257367A1 (en) Allogeneic vaccine and methods to synthesize same
Sabzevari et al. Human cytotoxic T-cells suppress the growth of spontaneous melanoma metastases in SCID/hu mice
JPWO2004110139A1 (ja) ヒト由来免疫担当細胞の製造方法
Perdrizet et al. Animals bearing malignant grafts reject normal grafts that express through gene transfer the same antigen.
Hellstrom et al. Therapeutic vaccination with tumor cells that engage CD137
JP2006509830A (ja) 癌予防用ハイブリッド細胞ワクチンの調製および投与
CA2237300C (en) Murine model for human carcinoma
JPH10504454A (ja) キメラ免疫無防備状態動物における長期間異種骨髄性およびリンパ性細胞生産
Leblond et al. The SCID mouse mutant: definition and potential use as a model for immune and hematological disorders
CN109891238A (zh) 免疫治疗剂的剂量确定
US20110159043A1 (en) Allogeneic vaccine and methods to synthesize same
WO2023060179A1 (en) Generation of t cell lines with specificity against one or more neoantigens
Egawa et al. Protection against metastasis by immunization with an allogeneic lymphocyte antigen
Walker Growth of human tumor-cell lines in immunodeficient scid and immune reconstituted human-pbl-scid mice-an improved in-vivo model for the study of human malignancy
Zheng Resetting the T Cell Repertoire in Prostate Cancer Bearing Host
Franchini Development of a model of humanized mouse to study the cross-talk between tumor and immune system and of a therapeutic approach for pancreatic cancer with human dendritic cells loaded with post-apoptotic tumors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref country code: US

Ref document number: 1997 939026

Date of ref document: 19970926

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref document number: 2237300

Country of ref document: CA

Ref country code: CA

Ref document number: 2237300

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1997 519058

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996942749

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1996942749

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1996942749

Country of ref document: EP